In Vitro-In Vivo Correlation of Posaconazole-Amphotericin B Combination against Candida albicans: In Vitro Interacting Concentrations Are Associated with In Vivo Free Drug Levels

被引:3
|
作者
Meletiadis, Joseph [1 ,2 ]
Beredaki, Maria-Ioanna [1 ]
Elefanti, Antigoni [1 ]
Pournaras, Spyros [1 ]
Muller, Anouk [2 ,3 ]
机构
[1] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Med Sch, Clin Microbiol Lab, Athens 12462, Greece
[2] Erasmus MC, Dept Med Microbiol & Infect Dis, NL-3015 CN Rotterdam, Netherlands
[3] Haaglanden Med Ctr, Dept Med Microbiol, NL-2512 VA The Hague, Netherlands
关键词
amphotericin B; posaconazole; combination therapy; Candida albicans; in vitro-in vivo correlation; NEUTROPENIC-MOUSE; FLUCONAZOLE; THERAPY; PHARMACODYNAMICS; ASPERGILLOSIS; ENDOCARDITIS; ITRACONAZOLE; ANTAGONISM; TRIAZOLE; MODEL;
D O I
10.3390/jof9040434
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The in vitro/in vivo correlation of antifungal combination testing is necessary in order to assess the efficacy of combination regimens. We, therefore, attempted to correlate in vitro chequerboard testing of posaconazole (POS) and amphotericin B (AMB) with the in vivo outcome of combination therapy against experimental candidiasis in a neutropenic murine model. The AMB + POS combination was tested against a Candida albicans isolate. In vitro, a broth microdilution 8 x 12 chequerboard method with serial two-fold drug dilutions was used. In vivo, CD1 female neutropenic mice with experimental disseminated candidiasis were treated with i.p. AMB and p.o. POS alone and in combination at three effective doses (ED20, ED50 and ED80 corresponding to 20%, 50% and 80% of maximal effect, respectively). CFU/kidneys after 2 days were determined. The pharmacodynamic interactions were assessed based on Bliss independence interaction analysis. In vitro, a Bliss antagonism of -23% (-23% to -22%) was observed at 0.03-0.125 mg/L of AMB with 0.004-0.015 mg/L of POS, while a Bliss synergy of 27% (14%-58%) was observed at 0.008-0.03 mg/L of AMB with 0.000015-0.001 mg/L of POS. In vivo, Bliss synergy (13 +/- 4%) was found when an AMB ED20 of 1 mg/kg was combined with all POS ED 0.2-0.9 mg/kg, while Bliss antagonism (35-83%) was found for the combinations of AMB ED50 2 mg/kg and ED80 3.2 mg/kg with POS ED80 of 0.9 mg/kg. Free drug serum levels of POS and AMB in in vivo synergistic and antagonistic combinations were correlated with the in vitro synergistic and antagonistic concentrations, respectively. Both synergistic and antagonistic interactions were found for the AMB + POS combination. POS compromised the efficacy of high effective AMB doses and enhanced low ineffective AMB doses. In vitro concentration-dependent interactions were correlated with in vivo dose-dependent interactions of the AMB + POS combination. In vivo interactions occurred at free drug serum levels close to in vitro interacting concentrations.
引用
收藏
页数:11
相关论文
共 25 条
  • [1] In vitro-in vivo correlation for posaconazole and voriconazole against aspergillosis
    Mavridou, E. M.
    Meletiadis, J. M.
    Melchers, W. J. G.
    Mouton, J. W.
    Verweij, P. E.
    MYCOSES, 2009, 52 : 26 - 26
  • [2] Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo
    Cacciapuoti, A
    Gurnani, M
    Halpern, J
    Norris, C
    Patel, R
    Loebenberg, D
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (02) : 638 - 642
  • [3] In Vitro and In Vivo Efficacy of Amphotericin B Combined with Posaconazole against Experimental Disseminated Sporotrichosis
    Mario, Debora Nunes
    Guarro, Josep
    Santurio, Janio Morais
    Alves, Sydney Hartz
    Capilla, Javier
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (08) : 5018 - 5021
  • [4] In vitro activity of amphotericin B and fluconazole in combination with atorvastatin and moxifloxacin against Candida albicans
    Kustimur, S.
    Fadil, S. J.
    Kustimur, S.
    Kalkanci, A.
    MYCOSES, 2009, 52 : 32 - 32
  • [5] In Vitro and In Vivo Activity of Citral in Combination with Amphotericin B, Anidulafungin and Fluconazole against Candida auris Isolates
    de-la-Fuente, Inigo
    Guridi, Andrea
    Jauregizar, Nerea
    Eraso, Elena
    Quindos, Guillermo
    Sevillano, Elena
    JOURNAL OF FUNGI, 2023, 9 (06)
  • [6] In vitro synergistic activity of diketopiperazines alone and in combination with amphotericin B or clotrimazole against Candida albicans
    S. Nishanth Kumar
    Bala Nambisan
    C. Mohandas
    A. Sundaresan
    Folia Microbiologica, 2013, 58 : 475 - 482
  • [7] In vitro synergistic activity of diketopiperazines alone and in combination with amphotericin B or clotrimazole against Candida albicans
    Kumar, S. Nishanth
    Nambisan, Bala
    Mohandas, C.
    Sundaresan, A.
    FOLIA MICROBIOLOGICA, 2013, 58 (06) : 475 - 482
  • [8] Posaconazole Exhibits In Vitro and In Vivo Synergistic Antifungal Activity with Caspofungin or FK506 against Candida albicans
    Chen, Ying-Lien
    Lehman, Virginia N.
    Averette, Anna F.
    Perfect, John R.
    Heitman, Joseph
    PLOS ONE, 2013, 8 (03):
  • [9] Dual Drug Loaded Topical Cubosomal Gel Against Candida Albicans: An In Vitro and In Vivo Proof of Concept
    Nath, A. Gowri
    Vaiphei, Klaudi K.
    Kumar, Ankaj
    Basrani, Sargun
    Jadhav, Ashwini
    Chakravarti, Rudra
    Ghosh, Dipanjan
    Bansal, Kuldeep K.
    Gulbake, Arvind
    AAPS PHARMSCITECH, 2025, 26 (03):
  • [10] In Vitro and In Vivo Antifungal Activity of AmBisome Compared to Conventional Amphotericin B and Fluconazole against Candida auris
    Herrada, Janet
    Gamal, Ahmed
    Long, Lisa
    Sanchez, Sonia P.
    McCormick, Thomas S.
    Ghannoum, Mahmoud A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (06)